ICH GCP E6(R3): The Future Starts Now The final version of ICH GCP E6(R3) is here—and it’s changing the way we design and conduct clinical trials. ICON’s regulatory experts will guide you through what’s new, what’s crit...
From bottlenecks to breakthroughs
Human-centred strategies for faster study starts
Read the whitepaperPreparing for ICH GCP E6(R3) implementation
A guide to assessing the impact, risk and requirements of the change
Read the whitepaperMeeting requirements for Joint Clinical Assessments
A planning guide for health technology developers
Read the whitepaper
Featured solutions
Blended solutions
Bespoke, seamless solutions to meet unique sponsor challenges.
Outcome Measures
A multi-faceted approach to identifying, selecting, and implementing evidence-based measures that matter to patients.
Biotech
ICON provides full service outsourcing and flexible support for biotech specific needs such as due diligence and asset valuation.
Cardiac Safety Solutions
End-to-end cardiac safety solutions, including ECG, event monitoring, BPM, long-term Holter monitoring, ECHO and MUGA studies.
Early Clinical and Bioanalytical Solutions
Innovative early clinical solutions that will advance your drug development strategy.
Site & Patient Solutions
Transforming recruitment through patient-centric trials and real-world, real-time data.
Market Access
Expertise in mission-critical pricing, market access, and reimbursement.
Specialty Laboratory Solutions
Supporting precision medicine programs across all phases of drug diagnostic co-development.
Webinars
Becoming a sponsor of choice for high-performing sites
3 December 2025. Register now.
Riding the data wave: How pharma can navigate disruptions in open claims
8 December 2025. Register now.
ICH GCP E6(R3): Preparing for global implementation, assessing the impact, risk and requirements of the change
16 December 2025. Register now.